Anti-LILRB4 chimeric antigen receptor T cell therapy(University of Texas Health Science Center/University of Texas Southwestern Medical Center)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-LILRB4 chimeric antigen receptor T cell therapy(University of Texas Health Science Center/University of Texas Southwestern Medical Center)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity

TargetsNot applicable

Therapy Area/IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity of Texas Southwestern Medical Center University Of Texas Health Science Center At Houston

China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Texas Southwestern Medical Center University Of Texas Health Science Center At Houston

Inactive CompaniesN/A

Active IndicationsHematologic NeoplasmsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A